Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
about
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in miceA combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor modelsEarly effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressureThe unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503The biology of the combretastatins as tumour vascular targeting agents.An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.Tumour targeting by microtubule-depolymerizing vascular disrupting agents.Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404)AVE8062: a new combretastatin derivative vascular disrupting agent.4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer.Monitoring the treatment efficacy of the vascular disrupting agent CA4P.Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.The Vascular-Disrupting Agent Combretastatin Impairs Splitting and Sprouting Forms of Physiological Angiogenesis
P2860
Q24606406-AFAEA5A5-923A-4BA6-80F4-5EA4A4017C12Q28543671-9AD67E83-303C-4069-B5C1-7455FC9BB8DEQ33278296-18A78D47-7592-4E46-833E-86507B4C7416Q34122191-B0C4A578-5BF9-46C9-9270-9E3B6121D951Q34296779-C7A030A2-0208-44D3-A6FB-A207B8B36C9AQ34680614-C8BF2760-DC7B-4E30-8269-41E81F622490Q34954063-CBD2D76D-EA22-4A10-8E3C-4C78DD30FBD6Q35832390-0EBBCD99-DDF0-45F2-99C5-32D40D7D329CQ37008845-A8EB19BD-A791-4467-AF1E-B968FE14393FQ37269347-56928821-CDE7-4B65-9067-3CD1F08C5828Q37598267-3AD482EB-0191-4D23-90EA-8A6912FC68AEQ39598565-A439575B-53A5-40AB-8837-357C406C13B7Q39620499-DF1F12E6-C290-43AA-882B-5D63397BEF68Q39657204-4E882D17-EEA1-491A-801A-C902F5B1155EQ39751688-C6E8BF4A-A7CA-46A7-AC5B-0903C92730EDQ42400154-4F1DDD95-A4FF-473E-B5BF-E653D0BD4539Q42794620-F6975DC5-67D2-46A5-96C2-B8F0A8E9C545Q44157516-42C86264-895A-42EA-BED1-102C32AD83D2Q56450717-F74FE605-C074-4E3E-A2F7-CB47AD5E8C72
P2860
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@ast
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@en
type
label
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@ast
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@en
prefLabel
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@ast
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@en
P2093
P2860
P356
P1476
Determinants of anti-vascular ...... osphate: role of nitric oxide.
@en
P2093
P2860
P2888
P304
P356
10.1054/BJOC.2000.1361
P407
P577
2000-09-01T00:00:00Z
P5875
P6179
1049184599